The dataset looked convincing until it did not. Small cohort studies often generate effect sizes that are difficult to ignore. In rare diseases, a handful of patients can produce dramatic responses—responses that would be diluted in larger, more heterogeneous populations. Publications in venues such as https://www.nejm.org routinely highlight these early signals, while registries cataloged at https://pubmed.ncbi.nlm.nih.gov expand the observational base. Variance behaves differently at small scale. Outliers exert disproportionate influence. A single responder can shift the mean. A single adverse event can redefine safety. The distribution becomes less stable, more sensitive to idiosyncrasy. There is also a temporal distortion. Small trials tend to be shorter, either by design or necessity. Outcomes are measured over compressed intervals. Durability remains untested.
The curve is observed at
its steepest point. Endpoint selection becomes strategic. Surrogate markers are favored—biomarkers, imaging findings, intermediate outcomes. They are measurable, responsive, and often regulatory-relevant. But they are also partial. The strength of small studies lies in their ability to move quickly. Hypotheses are tested, discarded, refined. Iteration accelerates. The weakness is that speed can outpace validation. Replication is the quiet currency of credibility. Small studies are easier to run, but harder to replicate in identical form. Subtle differences in protocol, population, or measurement can produce divergent results. The question is not whether small trials are valid. It is what kind of validity they offer. The dataset looked convincing until it did not. Small cohort studies often generate effect sizes that are difficult to ignore. In
rare diseases, a handful of patients can produce dramatic responses—responses that would be diluted in larger, more heterogeneous populations. Publications in venues such as https://www.nejm.org routinely highlight these early signals, while registries cataloged at https://pubmed.ncbi.nlm.nih.gov expand the observational base. Variance behaves differently at small scale. Outliers exert disproportionate influence. A single responder can shift the mean. A single adverse event can redefine safety. The distribution becomes less stable, more sensitive to idiosyncrasy. There is also a temporal distortion. Small trials tend to be shorter, either by design or necessity. Outcomes are measured over compressed intervals. Durability remains untested. The curve is observed at its steepest point. Endpoint selection becomes strategic. Surrogate markers are favored—biomarkers, imaging findings, intermediate outcomes. They are measurable, responsive, and
often regulatory-relevant. But they are also partial. The strength of small studies lies in their ability to move quickly. Hypotheses are tested, discarded, refined. Iteration accelerates. The weakness is that speed can outpace validation. Replication is the quiet currency of credibility. Small studies are easier to run, but harder to replicate in identical form. Subtle differences in protocol, population, or measurement can produce divergent results. The question is not whether small trials are valid. It is what kind of validity they offer. The dataset looked convincing until it did not. Small cohort studies often generate effect sizes that are difficult to ignore. In rare diseases, a handful of patients can produce dramatic responses—responses that would be diluted in larger, more heterogeneous populations. Publications
in venues such as https://www.nejm.org routinely highlight these early signals, while registries cataloged at https://pubmed.ncbi.nlm.nih.gov expand the observational base. Variance behaves differently at small scale. Outliers exert disproportionate influence. A single responder can shift the mean. A single adverse event can redefine safety. The distribution becomes less stable, more sensitive to idiosyncrasy. There is also a temporal distortion. Small trials tend to be shorter, either by design or necessity. Outcomes are measured over compressed intervals. Durability remains untested. The curve is observed at its steepest point. Endpoint selection becomes strategic. Surrogate markers are favored—biomarkers, imaging findings, intermediate outcomes. They are measurable, responsive, and often regulatory-relevant. But they are also partial. The strength of small studies lies in their ability to move quickly. Hypotheses
are tested, discarded, refined. Iteration accelerates. The weakness is that speed can outpace validation. Replication is the quiet currency of credibility. Small studies are easier to run, but harder to replicate in identical form. Subtle differences in protocol, population, or measurement can produce divergent results. The question is not whether small trials are valid. It is what kind of validity they offer. The dataset looked convincing until it did not. Small cohort studies often generate effect sizes that are difficult to ignore. In rare diseases, a handful of patients can produce dramatic responses—responses that would be diluted in larger, more heterogeneous populations. Publications in venues such as https://www.nejm.org routinely highlight these early signals, while registries cataloged at https://pubmed.ncbi.nlm.nih.gov expand the observational base. Variance
behaves differently at small scale. Outliers exert disproportionate influence. A single responder can shift the mean. A single adverse event can redefine safety. The distribution becomes less stable, more sensitive to idiosyncrasy. There is also a temporal distortion. Small trials tend to be shorter, either by design or necessity. Outcomes are measured over compressed intervals. Durability remains untested. The curve is observed at its steepest point. Endpoint selection becomes strategic. Surrogate markers are favored—biomarkers, imaging findings, intermediate outcomes. They are measurable, responsive, and often regulatory-relevant. But they are also partial. The strength of small studies lies in their ability to move quickly. Hypotheses are tested, discarded, refined. Iteration accelerates. The weakness is that speed can outpace validation. Replication is the quiet currency of
credibility. Small studies are easier to run, but harder to replicate in identical form. Subtle differences in protocol, population, or measurement can produce divergent results. The question is not whether small trials are valid. It is what kind of validity they offer. The dataset looked convincing until it did not. Small cohort studies often generate effect sizes that are difficult to ignore. In rare diseases, a handful of patients can produce dramatic responses—responses that would be diluted in larger, more heterogeneous populations. Publications in venues such as https://www.nejm.org routinely highlight these early signals, while registries cataloged at https://pubmed.ncbi.nlm.nih.gov expand the observational base. Variance behaves differently at small scale. Outliers exert disproportionate influence. A single responder can shift the mean. A single adverse event
can redefine safety. The distribution becomes less stable, more sensitive to idiosyncrasy. There is also a temporal distortion. Small trials tend to be shorter, either by design or necessity. Outcomes are measured over compressed intervals. Durability remains untested. The curve is observed at its steepest point. Endpoint selection becomes strategic. Surrogate markers are favored—biomarkers, imaging findings, intermediate outcomes. They are measurable, responsive, and often regulatory-relevant. But they are also partial. The strength of small studies lies in their ability to move quickly. Hypotheses are tested, discarded, refined. Iteration accelerates. The weakness is that speed can outpace validation. Replication is the quiet currency of credibility. Small studies are easier to run, but harder to replicate in identical form. Subtle differences in protocol, population, or
measurement can produce divergent results. The question is not whether small trials are valid. It is what kind of validity they offer. The dataset looked convincing until it did not. Small cohort studies often generate effect sizes that are difficult to ignore. In rare diseases, a handful of patients can produce dramatic responses—responses that would be diluted in larger, more heterogeneous populations. Publications in venues such as https://www.nejm.org routinely highlight these early signals, while registries cataloged at https://pubmed.ncbi.nlm.nih.gov expand the observational base. Variance behaves differently at small scale. Outliers exert disproportionate influence. A single responder can shift the mean. A single adverse event can redefine safety. The distribution becomes less stable, more sensitive to idiosyncrasy. There is also a temporal distortion. Small trials
